Two Sigma Advisers’s Tempest Therapeutics TPST Stock Holding History

Two Sigma Advisers’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-777	Closed	-$34K	–	2876
2022 Q1	$34K	Buy	+777	New	+$35.3K	﹤0.01%	2627
2021 Q2	–	Sell	-1,274	Closed	-$298K	–	2697
2021 Q1	$298K	Buy	1,274 +604	+90%	+$244K	﹤0.01%	2226
2020 Q4	$279K	Buy	+670	New	+$232K	﹤0.01%	2067
2020 Q3	–	Sell	-72	Closed	-$25K	–	2630
2020 Q2	$25K	Buy	+72	New	+$28.7K	﹤0.01%	2454
2018 Q4	–	Sell	-9	Closed	-$18K	–	2461
2018 Q3	$18K	Hold	9	–	–	﹤0.01%	2200
2018 Q2	$23K	Hold	9	–	–	﹤0.01%	2325
2018 Q1	$21K	Sell	9 -6	-40%	-$18K	﹤0.01%	2277
2017 Q4	$60K	Buy	+15	New	+$63K	﹤0.01%	2181

Other funds holding TPST

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Advisers's TPST Position: Q2 2022 in Review

Two Sigma Advisers sold out of Tempest Therapeutics (TPST) in Q2 2022, closing a stake of 777 shares — an estimated $34K sold.

Two Sigma Advisers first reported a position in TPST in Q4 2017 and held it in 8 quarters. The position peaked at $298K in Q1 2021. 16 funds tracked by Wall St. Rank hold TPST as of Q2 2022.

Two Sigma Advisers reported no remaining Tempest Therapeutics position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 777 Tempest Therapeutics shares in Q2 2022, an estimated $34K.
Two Sigma Advisers first reported a position in Tempest Therapeutics in Q4 2017 and held it in 8 quarters.
Two Sigma Advisers's Tempest Therapeutics position peaked at $298K in Q1 2021.
16 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.